SCHEMBL30228334

SCHEMBL30228334

Cc1ccccc1-c1cc(=O)oc2cc(NC(=O)C(C)C)ccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.60
▸ NPC1 O15118 4/20 0.60
▸ KMT2A Q03164 2/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ GAA P10253 1/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.60
▸ TDP1 Q9NUW8 2/20 0.57
▸ CA12 O43570 5/20 0.52
▸ CA9 Q16790 5/20 0.52
▸ CA1 P00915 3/20 0.52
▸ ALDH1A1 P00352 3/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ CA2 P00918 1/20 0.49
▸ KCNA3 P22001 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ MAPT P10636 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30228274 0.87 CA12 (0.70) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL30228174 0.85 NPC1 (0.57) RAB9ANPC1KMT2AMEN1GAA
SCHEMBL14176759 0.84 CA12 (0.72) RAB9ANPC1KMT2AMEN1GAA
SCHEMBL30228217 0.83 ALDH1A1 (0.54) RAB9ANPC1KMT2AGAATDP1
SCHEMBL30228340 0.83 ALDH1A1 (0.54) RAB9ANPC1KMT2AGAATDP1
SCHEMBL30228011 0.82 CA12 (0.50) RAB9ANPC1KMT2AGAASMN1; SMN2
SCHEMBL30228031 0.82 KCNA3 (0.47) RAB9ANPC1KMT2ATDP1CA12
SCHEMBL30228151 0.82 HPGD (0.73) RAB9ANPC1KMT2AGAASMN1; SMN2
SCHEMBL31711135 0.80 ALDH1A1 (0.48) RAB9ANPC1KMT2AMEN1GAA
SCHEMBL30228358 0.80 ALDH1A1 (0.51) RAB9ANPC1KMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-10-23 — — US disclosed
WO-2023034346-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT POLRMT, TFAM, POLM RAB9A 4007/4885NPC1 1952/4885KMT2A 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback